Alvotech SEC filings

Filings

Every filing, newest first. MAJOR and NOTABLE filings lead the app's feed; ROUTINE ones are kept here.

1. ROUTINE6-KAlvotechALVOW5d

   Alvotech submits Eylea 8mg biosimilar application

   • Submitted AVT29 biosimilar to Eylea 8mg in Europe
   • First global regulatory submission for Eylea 8mg biosimilar
   • Eylea 8mg accounted for 57% of sales in Q2 2026
2. ROUTINE6-KAlvotechALVOWOct 8

   Alvotech partners with LOTTE Biologics

   • Announced long-term manufacturing partnership
   • LOTTE Biologics will manufacture biosimilars at Syracuse facility
   • Syracuse facility has 40,000 liters bioreactor capacity
3. ROUTINE6-KAlvotechALVOWOct 5

   Alvotech gets FDA approval for new manufacturing capacity

   • FDA approved additional manufacturing capacity at Reykjavik facility for SIMLANDI
   • AVT02 drug substance can now be manufactured in two suites at Reykjavik
4. ROUTINE6-KAlvotechALVOWAug 31

   Foreign issuer report

5. ROUTINE6-KAlvotechALVOWAug 21

   Foreign issuer report

6. ROUTINE6-KAlvotechALVOWAug 19

   Foreign issuer report

7. ROUTINE6-KAlvotechALVOWJul 29

   Foreign issuer report

8. ROUTINE6-KAlvotechALVOWJul 1

   Foreign issuer report

9. NOTABLESCHEDULE 13D/AAlvotechALVOWJun 30

   Ownership stake disclosure by Celtic Holdings SCA (amended)

   Celtic Holdings SCA, filed by

10. ROUTINE6-KAlvotechALVOWJun 18

    Foreign issuer report

11. ROUTINE424B5AlvotechALVOWJun 16

    Securities offering

12. ROUTINEFWPAlvotechALVOWJun 16

    Securities offering

13. ROUTINEFWPAlvotechALVOWJun 15

    2 structured-note prospectuses

    Securities offering

    Show all 2

    • FWPSecurities offeringJun 15
    • 424B5Securities offeringJun 15
14. ROUTINE6-KAlvotechALVOWJun 15

    Foreign issuer report

15. ROUTINE6-KAlvotechALVOWJun 8

    Foreign issuer report

16. ROUTINE6-KAlvotechALVOWJun 4

    Foreign issuer report

17. ROUTINE6-KAlvotechALVOWMay 11

    Foreign issuer report

18. ROUTINE6-KAlvotechALVOWMay 4

    Foreign issuer report

19. ROUTINE6-KAlvotechALVOWMar 19

    Foreign issuer report

20. NOTABLESCHEDULE 13D/AAlvotechALVOWMar 12

    Ownership stake disclosure by Aztiq Pharma Partners S.a r.l. (amended)

    Aztiq Pharma Partners S.a r.l., filed by

21. ROUTINE6-KAlvotechALVOWFeb 27

    Foreign issuer report

22. ROUTINE6-KAlvotechALVOWFeb 5

    Foreign issuer report

23. ROUTINE6-KAlvotechALVOWFeb 2

    Foreign issuer report

24. ROUTINE6-KAlvotechALVOWJan 29

    Foreign issuer report

25. ROUTINE6-KAlvotechALVOWJan 7

    Foreign issuer report

26. ROUTINE6-KAlvotechALVOWJan 7

    Foreign issuer report

27. ROUTINE6-KAlvotechALVOWJan 6

    Foreign issuer report

28. ROUTINE6-KAlvotechALVOWJan 2

    Foreign issuer report

29. ROUTINE6-KAlvotechALVOWDec 23, 2025

    Foreign issuer report

30. ROUTINE6-KAlvotechALVOWDec 19, 2025

    Foreign issuer report

31. ROUTINE6-KAlvotechALVOWDec 17, 2025

    Foreign issuer report

32. ROUTINE6-KAlvotechALVOWNov 24, 2025

    Alvotech filed 6-K

    • Form Type: 6-K
    • Filing Date: 2025-11-24
33. ROUTINE6-KAlvotechALVOWNov 20, 2025

    Alvotech filed 6-K

    • Form Type: 6-K
    • Filing Date: 2025-11-20
34. ROUTINE6-KAlvotechALVOWNov 12, 2025

    Foreign issuer report

35. ROUTINE6-KAlvotechALVOWNov 6, 2025

    Foreign issuer report

36. ROUTINE6-KAlvotechALVOWNov 3, 2025

    Foreign issuer report

Older filings on EDGAR